日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial

纳武利尤单抗联合根治性放化疗治疗食管鳞状细胞癌(NOBEL):一项多中心、单臂、II期可行性试验

Nomura, Motoo; Sakanaka, Katsuyuki; Shimizu, Juko; Ohashi, Shinya; Katada, Chikatoshi; Watanabe, Akinori; Amanuma, Yusuke; Minashi, Keiko; Kato, Ken; Kojima, Takashi; Nagashima, Kengo; Kim, Ihhwa; Tada, Harue; Nakakura, Akiyoshi; Muto, Manabu

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer

基于拷贝数的癌基因优势可能提示 HER2 阳性胃癌中 ERBB2 依赖性和曲妥珠单抗反应

Wakatsuki, Takeru; Yamamoto, Noriko; Ishizuka, Naoki; Hironaka, Shuichi; Minashi, Keiko; Kadowaki, Shigenori; Hirano, Hidekazu; Shoji, Hirokazu; Yamaguchi, Toshifumi; Chin, Keisho; Ogura, Mariko; Nakayama, Izuma; Osumi, Hiroki; Ueki, Arisa; Kitano, Shigehisa; Boku, Narikazu; Yamaguchi, Kensei; Takahari, Daisuke

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

雷莫芦单抗治疗进展后联合伊立替康治疗雷莫芦单抗难治性晚期胃癌患者的随机III期试验:RINDBeRG试验

Sakai, Daisuke; Kadowaki, Shigenori; Kawabata, Ryohei; Hara, Hiroki; Satake, Hironaga; Takahashi, Masazumi; Takeno, Atsushi; Imai, Hiroo; Minashi, Keiko; Kawakami, Takeshi; Boku, Shogen; Matsuyama, Jin; Sakamoto, Yasuhiro; Sawada, Kentaro; Kataoka, Masato; Kawakami, Hisato; Shimokawa, Toshio; Boku, Narikazu; Satoh, Taroh

An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

一项观察性研究,旨在评估纳武利尤单抗联合化疗治疗未经治疗的晚期或复发性胃癌在日本真实世界中的有效性和安全性:G-KNIGHT 研究

Kadowaki, Shigenori; Otsuka, Tomoyuki; Minashi, Keiko; Nishina, Shinichi; Yabusaki, Hiroshi; Inagaki, Chiaki; Nishina, Tomohiro; Yasui, Hisateru; Matsuoka, Hiroshi; Machida, Nozomu; Tsuda, Masahiro; Nagashima, Fumio; Hosaka, Hisashi; Matsubara, Junichi; Arai, Hiroyuki; Ida, Satoshi; Kimijima, Yuya; Matsuda, Yuko; Muto, Manabu; Muro, Kei

Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)

曲妥珠单抗-德鲁替康治疗 HER2 阳性晚期胃癌日本患者的真实世界疗效和安全性(EN-DEAVOR 研究)

Kawakami, Hisato; Nakanishi, Koki; Makiyama, Akitaka; Konishi, Hirotaka; Morita, Satoshi; Narita, Yukiya; Sugimoto, Naotoshi; Minashi, Keiko; Imano, Motohiro; Inamoto, Rin; Kodera, Yasuhiro; Kume, Hiroki; Yamaguchi, Keita; Hashimoto, Wataru; Muro, Kei

Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

雷莫芦单抗联合化疗治疗对铂类化疗耐药/不耐受的胃肠道神经内分泌癌患者:一项多中心观察性回顾性研究(WJOG13420G)

Matsubara, Yuki; Masuishi, Toshiki; Hosoda, Waki; Hirano, Hidekazu; Mishima, Saori; Takahashi, Hiroyuki; Otsuka, Tomoyuki; Kawasaki, Kenta; Kawakami, Takeshi; Yanagihara, Kazuhiro; Shimura, Takaya; Komoda, Masato; Murayama, Kozue; Minashi, Keiko; Yamamoto, Yoshiyuki; Shinohara, Yudai; Nishina, Shinichi; Musha, Nobuyuki; Kato, Kyoko; Kawakami, Kentaro; Shinozaki, Katsunori; Tsuchihashi, Kenji; Ando, Takayuki; Kito, Yosuke; Makiyama, Akitaka; Mitani, Seiichiro; Hino, Kaori; Izawa, Naoki; Oze, Isao; Muro, Kei

Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study

Tasurgratinib治疗胆管癌或胃癌患者:首次人体I期研究的扩展部分

Morizane, Chigusa; Ueno, Makoto; Ioka, Tatsuya; Tajika, Masahiro; Ikeda, Masafumi; Yamaguchi, Kensei; Hara, Hiroki; Yabusaki, Hiroshi; Miyamoto, Atsushi; Iwasa, Satoru; Muto, Manabu; Takashima, Tsutomu; Minashi, Keiko; Komatsu, Yoshito; Nishina, Tomohiro; Nakajima, Takako Eguchi; Takeno, Atsuchi; Moriwaki, Toshikazu; Furukawa, Masayuki; Sahara, Takatoshi; Ikezawa, Hiroki; Nomoto, Maiko; Takashima, Shuya; Uehara, Taisuke; Funasaka, Setsuo; Yashiro, Masakazu; Furuse, Junji

Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)

循环肿瘤DNA在HER2阳性晚期胃癌中的临床意义:一项双重HER2和PD-1靶向治疗Ib期试验的合作研究(Ni-High)

Osumi, Hiroki; Wakatsuki, Takeru; Ooki, Akira; Chin, Keisho; Shoji, Hirokazu; Ogura, Mariko; Nakayama, Izuma; Yamamoto, Noriko; Hirano, Hidekazu; Hara, Hiroki; Minashi, Keiko; Shinozaki, Eiji; Kato, Ken; Ishizuka, Naoki; Kitano, Shigehisa; Takeuchi, Kengo; Boku, Narikazu; Yamaguchi, Kensei; Takahari, Daisuke

A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G

一项针对伴有严重腹膜转移的胃癌患者的多中心 II 期研究,评估 mFOLFOX6 联合纳武利尤单抗的疗效:WJOG16322G

Wakabayashi, Munehiro; Masuishi, Toshiki; Ogata, Takatsugu; Hanamura, Fumiyasu; Furuta, Mitsuhiro; Yamamoto, Yoshiyuki; Kawakami, Kentaro; Hirano, Hidekazu; Kito, Yosuke; Izawa, Naoki; Takahashi, Naoki; Matsumoto, Toshihiko; Kawakami, Hisato; Ando, Takayuki; Minashi, Keiko; Kudo, Chiho; Yoshimura, Kenichi; Muro, Kei

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study

接受曲妥珠单抗德鲁替康治疗的HER2阳性胃癌患者的预后因素和治疗反应:EN-DEAVOR研究的二次分析

Nakanishi, K; Sugimoto, N; Kodera, Y; Kawakami, H; Makiyama, A; Konishi, H; Morita, S; Narita, Y; Minashi, K; Imano, M; Inamoto, R; Nishina, T; Kawakami, T; Hagiwara, M; Kume, H; Yamaguchi, K; Hashimoto, W; Muro, K